Related references
Note: Only part of the references are listed.CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes.
A. Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Evaluation of CTL antigen 4 (CTLA-4) expression as prognostic factor in non-small cell lung cancer (NSCLC).
F. Grossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
Evan M. Hersh et al.
INVESTIGATIONAL NEW DRUGS (2011)
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
Elisabeth Quoix et al.
LANCET ONCOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
S. J. O'Day et al.
ANNALS OF ONCOLOGY (2010)
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Jeffrey Weber
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Lawrence Fong et al.
CANCER RESEARCH (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues
Giao Q. Phan et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung
J. L. Stanford et al.
EUROPEAN JOURNAL OF CANCER (2008)
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
James C. Yang et al.
JOURNAL OF IMMUNOTHERAPY (2007)
GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development
Vincent G. Brichard et al.
VACCINE (2007)
A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis
Charles Butts et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Therapeutic vaccination with Epidermal Growth Factor (EGF) in advanced lung cancer - Analysis of pooled data from three clinical trials
Gisela Gonzalez et al.
HUMAN VACCINES (2007)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Regulatory T cells in immune surveillance and treatment of cancer
T Yamaguchi et al.
SEMINARS IN CANCER BIOLOGY (2006)
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
E Contardi et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients
D Atanackovic et al.
JOURNAL OF IMMUNOLOGY (2004)
Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy
G Gonzalez et al.
ANNALS OF ONCOLOGY (2003)
Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor
T Crombet et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2001)
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation
S Read et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
